UnitedHealth Didn't Build a Flywheel. It Renamed One and Called It a Strategy.

On April 11, 2011, UnitedHealth Group held a launch for a brand-new health-services company called Optum. There was just one wrinkle: the company already existed. What got announced that day was a name. Underneath it sat three businesses UnitedHealth had been running for years — its services arm OptumHealth, its data subsidiary Ingenix, and a pharmacy-benefit operation it had inherited through its 2005 acquisition of PacifiCare Health Systems¹⁰. Combined, they were already doing $25 billion in revenue and serving more than 60 million people.¹ Nothing was founded. Nothing was built. A logo was placed over a pile of assets the company had owned all along — and a decade of strategy mythology began.

The official story is that UnitedHealth invented a brilliant flywheel: an insurer that built a health-services empire to feed itself, by design, from a blank sheet. The truer story is that it had the pieces lying around, gave them a shared name, and discovered — afterward — that owning both sides of a transaction is a license to print money. New Coke had a focus group. Optum had a re-brand. The plan was mostly a label.

Three businesses, one name, and a convenient bit of timing

Look at what actually happened in 2011 and the master-plan narrative thins out fast. OptumHealth kept its name. Prescription Solutions became OptumRx. And Ingenix — a data-and-analytics business that had been operating since the 1990s — became OptumInsight.¹ That last rename carried baggage the press release didn't mention. Ingenix had been forced to shut down the out-of-network benchmarking databases at the center of a settlement with the New York Attorney General, and trade press at the time noticed that a tarnished name was being quietly retired right as the new brand went up. UnitedHealth's spokeswoman denied the rebrand had anything to do with the bad publicity.⁸ The timeline is its own kind of testimony.

Here is the thesis, plainly: Optum was not a flywheel UnitedHealth engineered. It was a vertically integrated empire it assembled opportunistically — and then rationalized into a strategy after the fact. That distinction matters, because the very thing that makes the integration valuable is now the thing that makes it legally fragile. The synergy story and the antitrust liability are two sides of the same coin.

Why owning both ends of the transaction is so quietly lucrative

Strip the branding away and look at the mechanism. UnitedHealthcare is an insurer — it collects premiums and pays for care. Optum is a health-services company — it runs the pharmacy benefits, the data analytics, and a vast roster of physicians and clinics. When you own both, the money the insurer pays out doesn't leave the building. It moves from one pocket to another. A claim UnitedHealthcare would once have paid to an outside doctor, an outside data vendor, an outside pharmacy middleman, can now be routed to an Optum doctor, an Optum data platform, an Optum pharmacy operation — and the margin that used to walk out the door stays home. The insurer's cost is the services arm's revenue.

That is why Optum grew up to rival the parent. In full-year 2024, Optum did $253 billion in revenue, up 12% year over year, led by its pharmacy and health businesses, while UnitedHealthcare did $298.2 billion — the two halves now roughly the same size, inside a company doing about $400 billion in total.²³ The acquisitions follow the same logic. In 2015 UnitedHealth bought the pharmacy-benefit manager Catamaran at $61.50 a share to bulk up OptumRx — a business expected to fulfill more than 400 million prescriptions that year.⁴ In 2021 it agreed to buy Change Healthcare and fold it into OptumInsight, deepening its grip on the data plumbing that flows between payers and providers.⁵ Each deal widened the road; each deal kept more of the toll inside.

The same loop that prints money is the one the DOJ wants to cut

The integration runs on two flows: data and referrals. The insurer knows what care every patient is getting and what it costs; the services arm decides who provides that care. When those two sit inside one company, the data tells the referrals where to point, and the referrals feed more data back. It is a closed loop — and a closed loop where one firm both sets the price and supplies the product is exactly what an antitrust enforcer circles. In February 2024 the DOJ opened an investigation into precisely that question: the relationship between UnitedHealthcare's insurance unit and Optum's health-services arm.⁶ The reporting noted that Optum has been described as the largest employer of physicians in the country — a striking claim, though one attributed to the press rather than nailed down in any filing.⁶ The investigators were not chasing a side issue. They were aiming at the seam that makes the whole machine work.

Isn't this just a well-run flywheel that critics resent?

The fair objection is that every great integrated business gets accused of playing dirty simply because it's winning, and that vertical integration in healthcare can genuinely lower costs and coordinate care better than a fragmented system of strangers billing each other. That's real, and it deserves a straight answer. But two facts complicate the tidy synergy story. First, the integration is not frictionlessly value-accretive: UnitedHealth's 2024 medical care ratio rose to 85.5% from 83.2% the year before, meaning the insurer was paying out a bigger share of every premium dollar even as Optum's revenue climbed 12%.⁹ Owning both sides did not make the squeeze disappear. Second, the antitrust risk is not symmetrical with every headline. The DOJ's November 2024 complaint over the Amedisys acquisition was actually a horizontal case — about overlap between two home-health businesses — and notably did not allege harm from the payer-provider integration itself.⁷ The honest read is that the structural threat to the integration is real but specific, not a blanket war on the model. The vertical loop is powerful and legally exposed; it is also, so far, still standing.

UnitedHealth didn't draw up a flywheel and then go build it. It accumulated the parts, gave them a name in 2011, and grew into the realization that an insurer who owns the doctor, the pharmacy, and the data never has to let a dollar of care leave the family. That is a genuinely formidable position — $400 billion of it. But a machine that keeps the money in by closing the loop is, by definition, a machine that closes a loop, and closed loops are what enforcers exist to pry open. UnitedHealth's genius was never the plan. It was noticing, after the fact, that it had already built the thing — and the same insight has now arrived, pre-digested, on a desk at the Department of Justice.